Table 3.

Sero-positivity using competitive Luminex Immunoassay and cervical DNA-positivity to quadrivalent HPV vaccine types at baseline by group

	n (%)
Overall	HPV-6 N=135	HPV-11 N=135	HPV-16 N=135	HPV-18 N=135
Sero-positive and DNA-positive	0 (0)	1 (1)	6 (4)	1 (1)
Sero-positive and DNA-negative	39 (29)	16 (12)	29 (22)	24 (18)
Sero-negative and DNA-positive	0 (0)	0 (0)	2 (2)	1 (1)
Sero-negative and DNA-negative	96 (71)	118 (87)	98 (73)	109 (81)
Group 1 CD4 nadir<=350, on HAART	HPV-6 N=43	HPV-11 N=43	HPV-16 N=43	HPV-18 N=43
Sero-positive and DNA-positive	0 (0)	1 (2)	3 (7)	1 (2)
Sero-positive and DNA-negative	15 (35)	7 (16)	8 (19)	10 (23)
Sero-negative and DNA-positive	0 (0)	0 (0)	0 (0)	1 (2)
Sero-negative and DNA-negative	28 (65)	35 (81)	32 (74)	31 (72)
Group 2 CD4 nadir > 350, current CD4 350–500, not on HAART	HPV-6 N=46	HPV-11 N=46	HPV-16 N=46	HPV-18 N=46
Sero-positive and DNA-positive	0 (0)	0 (0)	2 (4)	0 (0)
Sero-positive and DNA-negative	9 (20)	4 (9)	10 (22)	7 (15)
Sero-negative and DNA-positive	0 (0)	0 (0)	1 (2)	0 (0)
Sero-negative and DNA-negative	37 (80)	42 (91)	33 (72)	39 (85)
Group 3 CD4 nadir>350, current CD4 > 500, not on HAART	HPV-6 N=46	HPV-11 N=46	HPV-16 N=46	HPV-18 N=46
Sero-positive and DNA-positive	0 (0)	0 (0)	1 (2)	0 (0)
Sero-positive and DNA-negative	15 (33)	5 (11)	11 (24)	7 (15)
Sero-negative and DNA-positive	0 (0)	0 (0)	1 (2)	0 (0)
Sero-negative and DNA-negative	31 (67)	41 (89)	33 (72)	39 (85)